Literature DB >> 25768997

Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25768997

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  10 in total

Review 1.  Novel agents in follicular lymphoma: choosing the best target.

Authors:  Laurie H Sehn
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Authors:  Ranjana H Advani; Daniel Lebovic; Andy Chen; Mark Brunvand; Andre Goy; Julie E Chang; Ephraim Hochberg; Sreeni Yalamanchili; Robert Kahn; Dan Lu; Priya Agarwal; Randall C Dere; Hsin-Ju Hsieh; Surai Jones; Yu-Waye Chu; Bruce D Cheson
Journal:  Clin Cancer Res       Date:  2016-09-06       Impact factor: 12.531

Review 3.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 4.  The landscape of new drugs in lymphoma.

Authors:  Anas Younes; Stephen Ansell; Nathan Fowler; Wyndham Wilson; Sven de Vos; John Seymour; Ranjana Advani; Andres Forero; Franck Morschhauser; Marie Jose Kersten; Kensei Tobinai; Pier Luigi Zinzani; Emanuele Zucca; Jeremy Abramson; Julie Vose
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

Review 5.  Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

Authors:  D MacDonald; A Prica; S Assouline; A Christofides; T Lawrence; L H Sehn
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

Review 6.  Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.

Authors:  Deepa Jagadeesh; Mitchell R Smith
Journal:  Curr Treat Options Oncol       Date:  2016-10

Review 7.  Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Authors:  Helen Ma; Ahmed Sawas
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

8.  Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.

Authors:  D Lu; W R Gillespie; S Girish; P Agarwal; C Li; J Hirata; Y-W Chu; M Kagedal; L Leon; V Maiya; J Y Jin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-05-23

9.  TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.

Authors:  Yung-Jue Bang; Toshimi Takano; Chia-Chi Lin; Adedigbo Fasanmade; Huyuan Yang; Hadi Danaee; Takayuki Asato; Thea Kalebic; Hui Wang; Toshihiko Doi
Journal:  Cancer Res Treat       Date:  2017-05-10       Impact factor: 4.679

10.  Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.

Authors:  Tomohiro Kinoshita; Kiyohiko Hatake; Kazuhito Yamamoto; Yusuke Higuchi; Satsuki Murakami; Yasuhito Terui; Masahiro Yokoyama; Dai Maruyama; Shinichi Makita; Yukari Hida; Tomohisa Saito; Kensei Tobinai
Journal:  Jpn J Clin Oncol       Date:  2021-01-01       Impact factor: 3.019
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.